DMAC Healthcare

DiaMedica Therapeutics Inc.

$10.00+7.64%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 539.3M USD
Enterprise value: 495.9M USD
Full-time employees: 35

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 0.97 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.97 vs peers 0.63)
Not enough data: growth

Would rank #932 of 1,157 fully scored healthcare companies (bottom 20%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 104% from December 2022 to August 2026.
DiaMedica Therapeutics had 104% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.DiaMedica Therapeutics had 104% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, DiaMedica Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
DiaMedica Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
DiaMedica Therapeutics has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

33/ 100

Oct 5 33 → Nov 4 33

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-7.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-7.9%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-5.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield7.1%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

11/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-83.4%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-93.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -9.76Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-97.9%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.97

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.01Sector median: 0.6250 · MAD: 0.3380

Current ratio6.72×

SEC filings · latest balance sheetReported value33% base weight · Z-score 2.99Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.06Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about DiaMedica Therapeutics

Is DiaMedica Therapeutics getting weaker?: A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 33/100 since Oct 28, 2026.
How is DiaMedica Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.0% vs peers 1.5% (weaker than 100% of peers).
Is DiaMedica Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is DiaMedica Therapeutics?: Less profitable than most of its peers. Profitability scores 11/100 against 1,393 healthcare peers. Return on assets -83.4% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -83.4% vs peers 1.7% (weaker than 100% of peers).
How risky is DiaMedica Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 93% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 93% of peers). Beta 0.97 vs a peer median of 0.63 (weaker than 70% of peers).Beta 0.97 vs peers 0.63 (weaker than 70% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-29.8%	-39.8%	-35.8%	-52.7%	-53.4%	▼ 0.6 pts
Return on equity (ROE)	-30.9%	-43.0%	-38.0%	-60.0%	-58.4%	▲ 1.6 pts
Current ratio	29.82×	15.61×	19.27×	8.28×	11.81×	▲ 43%

DMAC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 0.97 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.97 vs peers 0.63)

Not enough data: growth

Would rank #932 of 1,157 fully scored healthcare companies (bottom 20%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 104% from December 2022 to August 2026.

DiaMedica Therapeutics had 104% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.DiaMedica Therapeutics had 104% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, DiaMedica Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

DiaMedica Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.

DiaMedica Therapeutics has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about DiaMedica Therapeutics

Is DiaMedica Therapeutics getting weaker?

A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 33/100 since Oct 28, 2026.

How is DiaMedica Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.0% vs peers 1.5% (weaker than 100% of peers).

Is DiaMedica Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is DiaMedica Therapeutics?

Less profitable than most of its peers. Profitability scores 11/100 against 1,393 healthcare peers. Return on assets -83.4% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -83.4% vs peers 1.7% (weaker than 100% of peers).

How risky is DiaMedica Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 93% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 93% of peers). Beta 0.97 vs a peer median of 0.63 (weaker than 70% of peers).Beta 0.97 vs peers 0.63 (weaker than 70% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-29.8%

-39.8%

-35.8%

-52.7%

-53.4%

▼ 0.6 pts

Return on equity (ROE)

-30.9%

-43.0%

-38.0%

-60.0%

-58.4%

▲ 1.6 pts

Current ratio

29.82×

15.61×

19.27×

8.28×

11.81×

▲ 43%